Agilent Technologies has announced a multi-year distribution agreement with digital pathology firm Proscia to offer a comprehensive digital diagnostic pathology system. Combining Agilent's pathology staining solutions with Proscia’s Concentriq Dx enterprise pathology platform will empower laboratories to transform diagnostic efficiency and quality.
Digital pathology is experiencing a new wave of adoption as laboratories seek to deliver on growing expectations for precision medicine amid a worsening pathologist shortage in the US set against rising biopsy volume. Proscia's Concentriq Dx scalable enterprise pathology platform powers primary diagnostic workflows from individual labs to even the largest laboratory networks. It offers a pathologist-centric user experience across a robust digital environment for viewing, managing, and analysing images, helping to drive efficiency.
Lou Welebob, VP and General Manager of Agilent’s Pathology division, Diagnostics and Genomics Group, commented: “We are excited to partner with Proscia, a trailblazer in digital pathology, to deliver an open, scalable, and flexible digital pathology workflow with enhanced capabilities. This distribution agreement of Proscia’s technology to Agilent’s pathology customers demonstrates our continued commitment to providing pathologists with solutions to streamline and leverage the results of their image analysis, resulting in improved patient outcomes.”
“Digital pathology is advancing a data-driven standard of care that leads to personalized diagnosis and treatment,” said David West, CEO of Proscia. “We are thrilled that Agilent, a worldwide leader in diagnostics, shares our vision. We look forward to accelerating this era of precision medicine for pathologists, laboratories, and patients through our partnership.”